AIA Group Ltd purchased a new stake in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) during the first quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 2,153 shares of the medical research company’s stock, valued at approximately $612,000.
Other institutional investors have also recently made changes to their positions in the company. Diversified Trust Co lifted its stake in shares of Amgen by 76.8% in the 4th quarter. Diversified Trust Co now owns 37,695 shares of the medical research company’s stock worth $10,857,000 after purchasing an additional 16,376 shares during the period. Provence Wealth Management Group lifted its stake in shares of Amgen by 11.9% in the 4th quarter. Provence Wealth Management Group now owns 1,445 shares of the medical research company’s stock worth $416,000 after purchasing an additional 154 shares during the period. Kinsale Capital Group Inc. lifted its stake in shares of Amgen by 33.0% in the 4th quarter. Kinsale Capital Group Inc. now owns 11,348 shares of the medical research company’s stock worth $3,269,000 after purchasing an additional 2,814 shares during the period. Global Wealth Management Investment Advisory Inc. raised its stake in Amgen by 2.4% during the 4th quarter. Global Wealth Management Investment Advisory Inc. now owns 4,733 shares of the medical research company’s stock worth $1,363,000 after acquiring an additional 109 shares during the period. Finally, Traynor Capital Management Inc. raised its stake in Amgen by 9.5% during the 4th quarter. Traynor Capital Management Inc. now owns 18,941 shares of the medical research company’s stock worth $5,455,000 after acquiring an additional 1,650 shares during the period. Hedge funds and other institutional investors own 76.50% of the company’s stock.
Insiders Place Their Bets
In other Amgen news, SVP Nancy A. Grygiel sold 2,117 shares of Amgen stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $313.09, for a total transaction of $662,811.53. Following the completion of the transaction, the senior vice president now directly owns 9,883 shares of the company’s stock, valued at $3,094,268.47. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.69% of the stock is owned by insiders.
Wall Street Analysts Forecast Growth
Amgen Price Performance
Shares of AMGN stock traded up $5.74 on Friday, reaching $330.83. The company’s stock had a trading volume of 2,191,011 shares, compared to its average volume of 2,717,037. The company has a current ratio of 1.42, a quick ratio of 0.98 and a debt-to-equity ratio of 11.96. The stock’s fifty day simple moving average is $309.18 and its 200-day simple moving average is $294.69. The company has a market capitalization of $177.47 billion, a price-to-earnings ratio of 47.26, a price-to-earnings-growth ratio of 2.91 and a beta of 0.58. Amgen Inc. has a 1 year low of $224.34 and a 1 year high of $333.85.
Amgen (NASDAQ:AMGN – Get Free Report) last posted its quarterly earnings data on Thursday, May 2nd. The medical research company reported $3.96 EPS for the quarter, topping the consensus estimate of $3.76 by $0.20. The company had revenue of $7.45 billion during the quarter, compared to analyst estimates of $7.45 billion. Amgen had a net margin of 12.74% and a return on equity of 156.21%. Amgen’s quarterly revenue was up 22.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.98 earnings per share. Analysts forecast that Amgen Inc. will post 19.47 earnings per share for the current fiscal year.
Amgen Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
Recommended Stories
- Five stocks we like better than Amgen
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Top 3 Beverage Stocks: Summer Earnings Reveal Key Trends
- Top Biotech Stocks: Exploring Innovation Opportunities
- This Financial Stock’s Earnings Signal a Buying Opportunity
- Are Penny Stocks a Good Fit for Your Portfolio?
- Social Platform Stock Hits New Highs: Is More Growth Ahead?
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.